PPT-CHARACTERIZATION AND MANAGEMENT OF SYNCHRONOUS DUAL HEMATOLOGICAL MALIGNANCIES
Author : susan | Published Date : 2022-06-11
Rouslan Kotchetkov MD PhD 1 Erin Ellison MD 2 McLean J PhD 1 Bryn Pressnail MD 1 Derek Nay MD 1 1 Simcoe Muskoka Regional Cancer Program 2 Department
Presentation Embed Code
Download Presentation
Download Presentation The PPT/PDF document "CHARACTERIZATION AND MANAGEMENT OF SYNCH..." is the property of its rightful owner. Permission is granted to download and print the materials on this website for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
CHARACTERIZATION AND MANAGEMENT OF SYNCHRONOUS DUAL HEMATOLOGICAL MALIGNANCIES: Transcript
Rouslan Kotchetkov MD PhD 1 Erin Ellison MD 2 McLean J PhD 1 Bryn Pressnail MD 1 Derek Nay MD 1 1 Simcoe Muskoka Regional Cancer Program 2 Department . Synchronous operation is provided by having all flipflops clocked simultaneously so that the outputs change coincident with each other when so instructed by the countenable ENP ENT inputs and internal gating This mode of operation eliminates the out Educational Objectives. Minimal Residual Disease. Flow Cytometry. MRD Sensitivity Using Flow Cytometry. By Disease State. Genetic Methods for MRD Quantification. Allele-Specific Oligonucleotide (ASO)-PCR. Welcome. Facilitator name. Position . at . university. Contact info. learning outcomes. By . the end of this module, . you should be . able to. :. Evaluate a variety of educational technologies on the basis of hands-on . . – . the way an author reveals the special qualities and personalities of a character in a story, making the character believable. . Analyzing Character Traits. We try to figure out what a character in a book is like by paying attention to the clues the author gives us. This is called “. Learning Goals. Immunotherapies in B-Cell Malignancies. Available Immunotherapies. OS in MM. Poor Outcome in High-Risk Myeloma. Immunotherapy. Potential for Success Without a Targetable Molecular Mutation. Bill . Molesworth. Vice President, Terrestrial Wireless Services. ORBCOMM Inc.. Intelligent Assets . Are Everywhere. Transportation . •. . Heavy Equipment . •. . Maritime. Industrial/Remote . Assets . June 28, 2018. Management of hematologic malignancies in older patients. Disclosures. for Tanya Wildes. Honorarium. Carevive. Systems. Research Funding. Janssen. Key issues (1). Are the considerations in older adults with hematologic malignancies different than in solid tumors?. Case Report. 60 year old male patient presented with a history of trauma to his scrotum 1 year ago after which he developed scrotal swelling and pain. He tried Ayurvedic and Siddha medication for nearly 6 months but his symptoms worsened. He consulted a local surgeon and was diagnosed to have right testicular abscess with Fournier Gangrene for which he underwent debridement and right orchiectomy. However despite regular dressing and debridement his wound did not heal. He was then diagnosed to have left testicular abscess and underwent left orchiectomy with further debridement but to no avail. Recently he started noticing urine leaking from his wound when he voided.. After receiving a request from the WTC Clinical Centers of Excellence to review certain myeloid disorders in terms of their status as malignancies, 1 the WTC Health Program has determined that, 2 e g A concise book for quick consultation, Flow Cytometry of Hematological Malignancies is a key resource for all those working in the field of hematological malignancies, particularly lymphoma and leukemia, including hematologists, pathologists, and oncologists. Divided into two sections, part one details the main antigens expressed by normal and abnormal cells. Part two provides an essential but comprehensive description of the hematological neoplastic diseases, grouped according to the latest WHO classifications. Full-color images of the most and least common diseases are included in this book so readers are able to compare and contrast their own results. Additionally, guidance is offered through practical tips for result interpretation providing an essential description of the most likely phenotypes. (Ice Age) Beta Maturity. Cryosphere Products Validation Team. Jeff Key, NOAA/NESDIS/STAR, Team Lead. Paul Meade, Cryosphere Products JAM. DR # 7132. CCR # 474-CCR-13-0945. DRAT discussion: April 19, 2013. June 2. nd. 2023. Roman Galetto, PhD. Preclinical Vice President. Forward-Looking Statements. This presentation contains “forward-looking” statements within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words such as “designed to”, “anticipate,” “expected,” “on track,” “plan,” “scheduled,” "should", and “will,” or the negative of these and similar expressions. . Koopmansch. , Benjamin; . Palmeira. , . Leonor. , . Charloteaux. , Benoit; Lambert, Frédéric. Department. of . Human. . Genetics. , CHU . Liege. . 4000. . Liege. . . Belgium. .. In the frame of the development of new analytical methods for the diagnostic of patients suffering of suspected inherited malignancies with poor access to rapid diagnosis due to a restricted number of analytical sites or the current use of non-comprehensive targeted panels, we . OUTLINE FOR SYNCHRONOUS MACHINES. Types. Construction. Synchronous reactance. Equivalent circuits. Regulation . S. teady . state . operation. Special generators. . Synchronous . motor. Power . factor control and .
Download Document
Here is the link to download the presentation.
"CHARACTERIZATION AND MANAGEMENT OF SYNCHRONOUS DUAL HEMATOLOGICAL MALIGNANCIES"The content belongs to its owner. You may download and print it for personal use, without modification, and keep all copyright notices. By downloading, you agree to these terms.
Related Documents